Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C

MLA

Moucari, Rami, et al. “Danoprevir, an HCV NS3/4A Protease Inhibitor, Improves Insulin Sensitivity in Patients with Genotype 1 Chronic Hepatitis C.” Gut, vol. 59, no. 12, Dec. 2010, p. 1694. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.247277842&authtype=sso&custid=ns315887.

APA

Moucari, R., Forestier, N., Larrey, D., Guyader, D., Couzigou, P., Benhamou, Y., Voitot, H., Vidaud, M., Seiwert, S., Bradford, B., Zeuzem, S., & Marcellin, P. (2010). Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut, 59(12), 1694.

Chicago

Moucari, Rami, Nicole Forestier, Dominique Larrey, Dominique Guyader, Patrice Couzigou, Yves Benhamou, Helene Voitot, et al. 2010. “Danoprevir, an HCV NS3/4A Protease Inhibitor, Improves Insulin Sensitivity in Patients with Genotype 1 Chronic Hepatitis C.” Gut 59 (12): 1694. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.247277842&authtype=sso&custid=ns315887.